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Platelet-activating factor acetylhydrolases are a
family of specialized phospholipase A2 enzymes.
They serve an anti-in¯ammatory function by
converting the proin¯ammatory autocoid, PAF, into
biologically inactive lyso-PAF, by the removal of the
sn-2 acetyl group of this glycerophospholipid.
Similarly, platelet-activating factor acetylhydrolases
can also degrade oxidatively modi®ed sn-2
polyunsaturated-fatty-acid-containing phospholipids,
which are toxic to cells. Platelet-activating factor
acetylhydrolase II is a recently cloned member of
this family of specialized phospholipases. Consistent
with a potential role of this intracellular enzyme in
protecting membrane phospholipids against oxida-
tive stress, platelet-activating factor acetylhydrolase
II has been shown to translocate from cytosol to
membranes in response to pro-oxidative stressors,
and overexpression of this enzyme decreases the
cytotoxic effects of these agents. The objective of
this study was to assess whether platelet-activating
factor acetylhydrolase II is involved in protecting
skin against oxidative stress. Platelet-activating factor
acetylhydrolase II protein was demonstrated in
human skin by immunohistochemistry, with the
highest levels of the enzyme found in sebaceous
glands and lesser amounts in epidermal keratino-
cytes. Treatment of epidermal cells with t-butyl-
hydroperoxide or ultraviolet B radiation resulted in
platelet-activating factor acetylhydrolase II trans-
location from cytosol to membranes. To assess the
role of this enzyme in epidermal function, a recom-
binant retroviral strategy was used to overexpress
platelet-activating factor acetylhydrolase II in the
human keratinocyte-derived cell line HaCaT.
Overexpression of platelet-activating factor acetyl-
hydrolase II protected HaCaT cells against apop-
tosis induced by oxidative stressors t-butylhydroper-
oxide and ultraviolet B radiation. Similar levels of
apoptosis, however, were seen in both control
and platelet-activating-factor-acetylhydrolase-II-over-
expressing HaCaT cells in response to C2 ceramide.
These studies demonstrate the presence of platelet-
activating factor acetylhydrolase II in a restricted
pattern in human skin, and provide evidence that
this specialized phospholipase is involved in protect-
ing this organ against oxidative stress through the
degradation of oxidatively modi®ed bioactive phos-
pholipids. Key words: apoptosis/keratinocytes/oxidative
stress/platelet-activating factor/platelet-activating factor
acetylhydrolase. J Invest Dermatol 119:913±919, 2002
P
latelet-activating factor (1-O-alkyl-2-acetyl-sn-glycero-
3-phosphocholine; PAF) is a potent phospholipid-
derived mediator implicated in a broad spectrum of
physiologic and pathologic activities, particularly in¯am-
mation and allergy (reviewed by Pinckard et al, 1994;
Prescott et al, 2000). A variety of human cell types including
polymorphonuclear leukocytes, macrophages, endothelial cells, and
keratinocytes both synthesize PAF and express functional PAF
receptors (PAF-R). The PAF-R is a G-protein-linked transmem-
brane protein that can signal through many second messenger
systems including phospholipases A2, C, and D, as well as by
activation of kinases including protein kinase C and mitogen-
activated protein kinases (reviewed by Izumi and Shimizu, 1995).
Accumulating evidence suggests that the PAF system is involved
in keratinocyte function and skin in¯ammation. Signi®cant levels of
PAF are not found in normal skin, but can be measured in various
in¯ammatory dermatoses ranging from psoriasis to urticaria
(Grandel et al, 1985; Mallet and Cunningham, 1985). Injection of
PAF into skin results in cutaneous in¯ammation within 1 h, which
clinically and histologically resembles an urticarial lesion (Archer et
al, 1984; Michel et al, 1987; Hellewell and Williams, 1989; Travers
et al, 1998). Human keratinocytes express functional PAF-Rs,
which can trigger the production of other pro-in¯ammatory
mediators including eicosanoids, interleukins IL-6, IL-8, and tumor
necrosis factor a (Pei et al, 1998; Dy et al, 1999). Other pro-
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oxidative stimuli such as tertiary butyl hydroperoxide (t-BuOOH)
and ultraviolet B (UVB) irradiation can also induce the production
of PAF or PAF-like species in epidermal cells (Dy et al, 1999;
Travers, 1999). Of signi®cance, recent studies have implicated PAF
in UVB-mediated immunosuppression via epidermal-produced
IL-10 (Watersheid et al, 2002).
The pathway for the acute synthesis of PAF is the sequential
actions of phospholipase A2 and PAF acetyltransferase upon 1-alkyl
glycerophosphocholines with a long chain unsaturated fatty acid
(often arachidonic acid) at the sn-2 position. The PAF-R not only
recognizes native PAF, but also 1-acyl 2-acetyl glycero-
phosphocholine analogs as well as sn-2 short-chained glycerophos-
phocholines created by free-radical-mediated fragmentation of
arachidonic acid or other unsaturated fatty acid (Murphy, 1996;
Marathe et al, 1999). This production of PAF-like lipids in response
to oxidative stress differs from the tightly controlled enzymatic
pathway.
PAF is inactivated by removal of the sn-2 acetate moiety through
the actions of a family of speci®c phospholipases termed platelet-
activating factor acetylhydrolases (PAF-AH) (reviewed by Stafforini
et al, 1997). Unlike phospholipase A2 enzymes, which hydrolyze
phospholipids with long chain acyl groups at the sn-2 position,
PAF-AHs selectively hydrolyze short-chained fatty acids at the sn-2
position of glycerophosphocholines. PAF-AH enzymes can also
inactivate short-chained PAF-like lipids produced as a consequence
of oxidative stress. In addition to their unusual speci®city, PAF-
AHs typically are in a fully activated state (Yanoshita et al, 1988;
Stafforini et al, 1991).
Both extracellular or plasma associated and intracellular or tissue
associated types of PAF-AHs have been described (Stafforini et al,
1997). Extracellular PAF-AH is a 43 kDa monomeric enzyme,
which is thought to regulate plasma PAF levels in the plasma.
Approximately 4% of the Japanese population have a mutation in
PAF-AH abolishing the activity of this enzyme. The presence of
this mutation has been reported to be a severity factor for the
development of severe asthma (Miwa et al, 1998). Two separate
intracellular types of PAF-AHs have been described (types I and II).
Type I PAF-AH has two isoforms, tentatively named Ia and Ib.
Isoform Ib is a heterotrimeric enzyme restricted to brain, the lack of
which results in malformation of the cerebral cortex (Miller±Dieker
lissencephaly) (Hattori et al, 1994).
The intracellular isoform II (PAF-AHII) is a 40 kDa monomer
most abundantly expressed in bovine liver and kidney (Hattori et al,
1995; 1996). Recent studies using MDBK cells have found that
PAF-AHII translocates from cytosol to membranes within 20 min
following exposure of the cells to pro-oxidative stressors.
Conversely, this enzyme translocates back to cytosol following
treatment with antioxidants (Matsuzawa et al, 1997). In addition,
overexpression of PAF-AHII in Chinese hamster ovary cells
inhibited apoptosis induced by the pro-oxidant t-BuOOH
(Matsuzawa et al, 1997). These ®ndings suggest that this enzyme
acts to degrade oxidatively fragmented phospholipids that are toxic
to the cell.
The objective of our studies was to assess whether human skin
expresses PAF-AHII. Because this enzyme has been hypothesized
to protect cells against oxidative stress, we tested whether
overexpression of the enzyme in an epidermal cell line could
protect against the cytotoxic effects of pro-oxidative stressors
including t-BuOOH and UVB.
MATERIALS AND METHODS
Reagents PAF, t-BuOOH, and routine chemicals were obtained from
Sigma (St. Louis, MO). Because of its chemical instability, t-BuOOH
bottles were discarded within 48 h after opening. Growth media and
supplements were purchased from Life Technologies (Gaithersburg, MD)
and fetal bovine serum from Intergen (Purchase, NY).
Cells Primary cultures of neonatal-foreskin-derived human
keratinocytes and ®broblasts were harvested and cultured as previously
outlined (Travers et al, 1996). The immortalized sebaceous gland cell line
SZ95 was grown in Sebomed medium as described previously
(Zouboulis et al, 1999).
Generation of monoclonal antibodies against PAF-AHII The
cDNA for the PAF-AHII (Hattori et al, 1996) was ligated into the
NdeI/HindIII sites of the pET21a vector (pET system, Novagen). After
the plasmid had been introduced into Escherichia coli strain BL21 (DE3),
protein was expressed as His-tagged protein by induction with 1 mM
isopropyl-b-D-thiogalactopyranoside. The protein was puri®ed using
nickel column chromatography (Novagen) according to the
manufacturer's protocol. Balb/c mice were immunized with the puri®ed
protein and monoclonal antibodies were produced using the PAI
myeloma cell line. Hybridoma cell lines were established according to
the standard protocol.
Immuno¯uorescence studies The presence of PAF-AHII protein in
skin was assessed by immuno¯uorescence studies using the monoclonal
antibody against human PAF-AHII whose synthesis is described above.
Biopsies of human normal skin were collected and immediately frozen in
Tissue-Tek, optimal cutting temperature (OCT), obtained from Sakura
Finetek Europe BV (Zauterwoude, The Netherlands). The frozen block
subsequently was stored at ±80°C until used. Six to eight micrometer
cryostat sections were obtained and stained with the monoclonal
antibody against PAF-AHII. Brie¯y, the sections were ®xed in ethanol
for 1 min, washed in ddH2O for 20±30 s, then washed with phosphate-
buffered saline (PBS) for 5 min, and then incubated with anti-PAF-AHII
monoclonal antibody diluted at 1:100 in PBS containing 3% bovine
serum albumin (BSA) for 1 h at room temperature. The sections were
washed three times with PBS, and then incubated with a ¯uorescein-
conjugated goat antimouse IgG polyclonal antibody diluted at 1:100 in
PBS containing 3% BSA for 1 h at room temperature, in the dark. After
the incubation with the conjugated ¯uorescent antibody the sections
were washed three times with PBS and mounted using Fluoromount-G
and cover slides. Immunostaining patterns were visualized using an
Olympus ¯uorescent microscope. As a control, extra sections from the
same specimen, following all the staining procedures, substituting the
PAF-AHII antibody with mouse IgG (Sigma) in the incubation with 3%
BSA, were stained at the same time.
HaCaT±PAF-AHII model system The immortalized human
keratinocyte derived cell line HaCaT (Boukamp et al, 1988) was a gift
from Dr. Petra Boukamp (German Cancer Research Center, Heidelberg,
Germany) and was cultured as previously reported (Travers et al, 1996).
To create HaCaT cells stably overexpressing PAF-AHII, the entire
human PAF-AHII cDNA was cloned into the MSCV 2.1 retroviral
vector and high titer replication-de®cient retrovirus was produced as
previously described (Pei et al, 1998). HaCaT cells were transduced with
MSCV 2.1PAF-AHII or empty MSCV 2.1 retrovirus (as control) using
polybrene, and infected cells were screened by using G418 as previously
reported (Pei et al, 1998). PAF-AHII protein was assessed by immuno-
blotting using the same monoclonal PAF-AHII antibody used in the
immuno¯uorescence studies. Brie¯y, con¯uent 10 cm dishes of
HaCaTM PAF-AHII and HaCaTM were washed twice with PBS and
lyzed with 1.5 ml of lysis buffer (RIPA) for 30 min, disrupted by
sonication in a vessel surrounded by ice for three 30 s periods at 45 s
intervals using a sonic dismembrator (Fischer Scienti®c, Pittsburgh, PA).
The cell lysate was centrifuged at 35,000 rpm for 10 min; protein in the
resultant supernatant was quantitated using a commercial kit (Bio-Rad),
and aliquots were placed in Eppendorf tubes and stored at ±80°C. The
samples were resolved by sodium dodecyl sulfate polyacrylamide gel
electrophoresis on a 12% acrylamide gel and blotted onto a nitrocellulose
membrane. The membrane was blocked with Tris-buffered saline (TBS)
containing 5% skim milk overnight at 4°C and then washed three times
with TBS containing 2% Tween 20 (T-TBS), incubated with the anti-
PAF-AHII monoclonal antibody diluted 1:3000 in TBS containing 5%
skim milk for 1 h, and incubated with a horseradish-peroxidase-conju-
gated goat antimouse antibody diluted 1:3000 in TBS containing 5%
skim milk. After washing the membrane four times with T-TBS,
peroxidase was detected by an enhanced chemiluminescence method
using an ECL Western Blotting Detection Set from Hyper®lm ECL
(Amersham Life Science). PAF-AHII distribution in membrane versus
cytosolic fractions of HaCaT cells was assessed as previously described
(Matsuzawa et al, 1997).
PAF-AH enzymatic activity PAF-AH enzymatic activity of HaCaT
cells was measured as previously described (Narahara and Johnson, 1993).
Brie¯y, 4±6 3 106 cells were trypsinized, washed with PBS, and
pelleted; the supernatant was aspirated and the pellets were frozen
(±80°C) until analyzed. The samples were thawed on ice and 500 ml of
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cold sucrose (0.25 M) was added to each tube. They were then sonicated
in a vessel surrounded by ice for ®ve periods of 10 s at 20 s intervals
using an ultrasonic device (Ultrasonic, Planeview, NY), and then
centrifuged at 12,000 3 g at 4°C. The resultant supernatant was
removed and assayed for PAF-AH enzymatic activity using 1-O-alkyl-2-
[3H]acetate-glycerophosphocholine as previously described (Narahara and
Johnson, 1993). Samples were run in triplicate.
Measurement of apoptosis in HaCaT cells HaCaTM or HaCaTM
PAF-AHII cells were plated at 8 3 105 cells in 10 cm dishes for 24 h.
Following washing with medium, the cells were treated with 200 mM t-
BuOOH or 100 mM of C2 ceramide, or irradiated with 400 J per m2 of
UVB (all in regular medium) as previously described (Barber et al, 1998).
The irradiator was an un®ltered Philips F20T12/UVB source
(270±390 nm; containing 2.6% UVC, 43.6% UVB, 53.8% UVA). The
intensity of the UV source was routinely measured using an International
Light radiometer equipped with a UVB detector. At various time points
following treatment, the cells were harvested by collection of supernatant
and trypsinization of adherent cells and pelleted. Caspase 3 proteolytic
activity in cell lysates was measured using a synthetic ¯uorogenic
substrate (DEVD-AMC, Alexid Biochemicals, San Diego, CA; Hurwitz
and Spandau, 2000). Brie¯y, the cells were suspended in lysis buffer
(50 mM PIPES, pH 7.0, 50 mM KCl, 5 mM ethyleneglycol-bis(b-
aminoethyl ether)-N,N,N¢,N¢-tetraacetic acid, 2 mM MgCl2, 1 mM
dithiothreitol) for 30 min on ice. Following removal of cellular debris by
centrifugation, an aliquot of the cell lysate was added to caspase 3
reaction buffer (100 mM HEPES, pH 7.5, 10% sucrose, 0.1% CHAPS,
10 mM dithiothreitol, 0.1 mg per ml bovine serum albumin, and 50 mM
CPP32-AMC substrate) and incubated at 37°C for 1 h. Release of the
¯uorescent AMC moiety was measured using a Hitachi F2000
Spectrophotometer (excitation, 380 nm; emission, 460 nm). The
¯uorescent intensity was converted to moles of AMC by comparison to
the ¯uorescent intensity of standards of AMC (7-amino-4
methylcoumarin; Molecular Probes, Eugene, OR). The speci®c activity
of caspase 3 in cell lysates was then determined after the total protein
concentration of the cell lysates was measured (Nano Orange Protein
Quanti®cation Reagent, Molecular Probes) and was expressed as pmoles
AMC per h per mg protein.
RESULTS
PAF-AHII expression in human skin Our ®rst studies assessed
whether PAF-AHII protein was expressed in human skin.
Immuno¯uorescence studies with a PAF-AHII speci®c
monoclonal antibody revealed expression of this protein in
normal human skin. As shown in Fig 1, sebaceous glands
exhibited the highest levels of PAF-AHII expression with lesser
amounts found in the epidermis. Weak PAF-AHII
immunoreactivity was expressed throughout the epidermis, yet
signi®cant levels of PAF-AHII immunoreactivity were not seen in
dermal ®broblasts or blood vessels. Examination of PAF-AHII
protein levels in primary cultures of human keratinocytes,
®broblasts, and the immortalized sebaceous gland cell line SZ95
(Zouboulis et al, 1999) revealed the highest levels of
immunoreactive protein in the sebaceous gland cell line (Fig 2).
These studies indicate that human skin expresses PAF-AHII protein
in a restricted pattern with the highest amounts of protein
associated with sebaceous glands/sebocytes.
Translocation of PAF-AHII protein Recent studies have
found that PAF-AHII translocates from cytosol to membranes
following exposure of the cells to the pro-oxidative stressor t-
BuOOH (Matsuzawa et al, 1997). The next studies assessed
whether the PAF-AHII expressed in epidermal cells translocates in
response to oxidative stressors. HaCaT keratincoytes were treated
with 100 mM t-BuOOH or irradiated with 600 J per m2 UVB and
the levels of PAF-AHII protein in cytosol versus membranes was
evaluated. As shown in Fig 3, resting HaCaT cells express
approximately equal amounts of PAF-AHII protein in membrane
versus cytosolic fractions. Treatment with UVB or t-BuOOH
resulted in increased levels of protein in the membrane over
cytosolic fractions.
HaCaT±PAF-AHII model system Through its ability to
recognize and inactivate biologically active PAF as well as
Figure 1. PAF-AHII expression in human
skin. Immuno¯uorescence staining of normal
human skin using a monoclonal anti-PAF-AHII
antibody. (A) Epidermis stained with anti-PAF-
AHII antibody (4003). (B) Control, using mouse
IgG (4003; bar: 60 mm). (C) Sebaceous glands
stained with anti-PAF-AHII antibody (1003). (D)
Control (1003; bar: 240 mm). (E) High power of
sebaceous glands stained with anti-PAF-AHII
antibody (4003). (F) Control (4003; bar: 60 mm).
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PAF-like lipids created in response to oxidative stress, PAF-AHII is
thought to play a protective role in the skin. Consistent with the
notion that PAF-AHII could protect cells against oxidative stress,
overexpression of this protein in Chinese hamster ovary cells
inhibits t-BuOOH-induced apoptosis (Matsuzawa et al, 1997). As
immuno¯uorescence studies suggest that human keratinocytes
express PAF-AHII, we created a model system using the human
keratinocyte-derived cell line HaCaT, which was genetically
engineered to overexpress PAF-AHII using a replication-de®cient
retrovirus. Northern blotting of HaCaT cells transduced with PAF-
AHII (HaCaTM PAF-AHII) or control transduced (HaCaTM)
demonstrated that both cell populations contained PAF-AHII
mRNA, with less than a 2-fold increase found in the HaCaTM
PAF-AHII cells (data not shown).
Immunoblotting studies revealed increased levels of PAF-AHII
protein in HaCaTM PAF-AHII over HaCaTM cells. Enzyme
activity studies demonstrated a greater than 3-fold increase in PAF-
AH activity in the HaCaTM PAF-AHII over HaCaTM cells
(Fig 4). Using this model system, the role of moderate over-
expression of PAF-AHII in a keratinocyte-derived cell line could
be assessed.
Protective effects of PAF-AHII overexpression on apoptosis
induced by t-BuOOH and UVB irradiation The next
experiments investigated whether overexpression of PAF-AHII in
HaCaT cells protects against apoptosis induced by oxidative
stressors such as t-BuOOH and UVB irradiation. Apoptosis was
assessed by measurement of caspase 3 enzymatic activity using a
¯uorescent substrate as outlined in Materials and Methods. Our
laboratory has previously demonstrated that caspase 3 enzymatic
levels correlate with other apoptotic measurements in epithelial
cells (Southall et al, 2001). HaCaTM and HaCaTM PAF-AHII cells
were treated with 100 mM t-BuOOH and incubated at 37°C, and
caspase 3 enzymatic activity was assessed at various times. As shown
in Fig 5, t-BuOOH treatment resulted in increased caspase 3
speci®c activity by 8 h in HaCaTM cells. Maximal levels of caspase
3 induction were seen by 12 h. HaCaTM PAF-AHII cells did not
exhibit increased caspase 3 enzymatic activity until 24 h, however.
Consistent with the cytotoxic effects described in other cell types,
HaCaTM cells treated with t-BuOOH began to detach from the
plate by 8 h. In contrast, the majority of HaCaTM PAF-AHII cells
remained attached to the plate and viable until 24 h. These studies
indicate that overexpression of PAF-AHII protein is protective
against cellular cytotoxicity induced by the oxidative stressor
t-BuOOH.
Recent studies suggest that UVB acts as a potent pro-oxidative
stimulus in human keratinocytes (Peus et al, 1998). As our previous
studies indicate that PAF and PAF-like lipids are produced by
epidermal cells in response to UVB (Barber et al, 1998; Dy et al,
1999), we tested whether overexpression of PAF-AHII could
protect against UVB-induced apoptosis. Irradiation of HaCaTM
and HaCaTM PAF-AHII cells with 400 J per m2 UVB resulted in
Figure 2. Measurement of PAF-AHII protein in keratinocytes,
®broblasts, and a sebaceous cell line. Protein (40 mg) was isolated
from primary cultures of neonatal-foreskin-derived human keratinocytes
(NHK), human ®broblasts (NHF), and SZ95 sebocytes, and run on a
15% sodium dodecyl sulfate polyacrylamide gel. PAF-AHII
immunoreactivity was determined using a monoclonal antibody. The
membranes were stripped and re-probed with an antibody against
b-actin.
Figure 3. Effect of t-BuOOH and UVB on distribution of PAF-
AHII levels in HaCaT keratinocytes. (A) HaCaT cells were treated
with 100 mM t-BuOOH for 2 h or were exposed to 600 J per m2 UVB.
Two or 4 h after UVB treatment the cellular cytosol and membrane
fractions were isolated by ultracentrifugation and run on a 15% sodium
dodecyl sulfate polyacrylamide gel; PAF-AHII immunoreactivity was
determined using a monoclonal antibody. (B) Immunoblots were
scanned and quanti®ed using NIH Image software. Each value is the
relative ratio and standard deviation of membrane to cytosol PAF-AHII
obtained from three independent experiments and normalized to the
untreated ratio. An asterisk represents a signi®cant difference between
translocation of PAF-AHII in untreated and treated cells using analysis of
variance with Neuman±Keuls as the post hoc test (p < 0.05).
Figure 4. Measurement of PAF-AHII protein and enzyme
activity in HaCaT cells. Protein (10 mg) was extracted from HaCaTM
PAF-AHII and control HaCaTM cells and immunoblotted using a
monoclonal PAF-AHII antibody. PAF-AH enzyme activities of cells are
listed below the corresponding immunoblot, and are the mean of three
separate samples. The standard deviation of the enzyme activity
measurements was less than 10%.
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caspase 3 activation (Fig 6). The levels of caspase 3 were
signi®cantly less in HaCaTM PAF-AHII versus HaCaTM cells at
8 and 12 h, however. Examination of the plates for detached cells
mirrored the caspase 3 enzymatic assays, with fewer adherent cells
in HaCaTM versus HaCaTM PAF-AHII cells until 24 h. These
®ndings indicate that increased levels of PAF-AHII protein delays
UVB-induced apoptosis.
Lack of protective effects of PAF-AHII overexpression on
apoptosis induced by C2 ceramide C2 ceramide is a short-
chained ceramide that induces apoptosis in many cell types (Obeid
and Hannun, 1995). Although C2 ceramide has been reported to
induce oxidative stress in mitochondria (Ballon et el, 1996), this
toxic lipid does not have the pro-oxidative effects of t-BuOOH or
UVB. Treatment of HaCaT cells with 100 mM C2 ceramide
resulted in apoptosis by 24 h as measured by enhanced caspase 3
induction (Fig 7). The amount of caspase 3 induction as well as
numbers of detached cells were similar in HaCaTM versus
HaCaTM PAF-AHII cells, however, suggesting that
overexpression of PAF-AHII does not protect against C2-
ceramide-induced apoptosis.
DISCUSSION
Keratinocytes are chronically exposed to a powerful oxidant agent
UVB, as well as endogenous sources of reactive oxygen species
from metabolic processes and also from in¯ammatory cells such as
neutrophils. As both oxidized lipids and the PAF system appear to
be involved in epidermal function/cutaneous in¯ammation,
characterization of the enzymes involved in the regulation of
these lipids is important. These studies demonstrate that human skin
contains the specialized phospholipase PAF-AHII, and provide
evidence that this enzyme could be involved in the protection of
this organ against the toxic effects of oxidative stress.
Accumulating evidence indicates that unsaturated fatty acids are a
target for oxidative stress. Indeed, reactive oxygen species have
been shown to spontaneously oxidize unsaturated fatty acyl chains
in membrane phospholipids (Zimmerman et al, 1995). Depending
upon the structure of the resultant product, oxidized lipids can have
biologic activities through activation of the PAF-R, as well as cause
cell damage and apoptosis through receptor-independent effects.
Thus, oxidized phospholipids need to be rapidly hydrolyzed to
prevent their cellular toxicities.
PAF-AHII is a recently cloned protein whose enzymatic activity
is that of a phospholipase A2, yet restricted to the hydrolysis of
short-chained sn-2 acyl groups. Several features of this enzyme
suggest that it could be involved in protecting cells against oxidized
phospholipids. First, PAF-AHII is constitutively active, unlike
other phospholipase A2 enzymes (Blank et al, 1981; Stremler et al,
1989; Tjoelker et al, 1995). Second, studies using MDBK renal cells
and now HaCaT keratinocytes indicate that PAF-AHII translocates
from cytosol to membranes following exposure to oxidants. The
ability of this active enzyme to rapidly translocate to membranes
would ensure that oxidized unsaturated acyl groups in the sn-2
position of phospholipids are rapidly degraded. Finally, over-
expression of PAF-AHII in Chinese hamster ovary cells protects
against t-BuOOH-induced apoptosis (Matsuzawa et al, 1997). Our
studies are also consistent with the notion that this enzyme is
involved in protecting cells against oxidized phospholipids.
Figure 6. UVB-radiation-induced apoptosis in HaCaTM and
HaCaTM PAF-AHII cells. HaCaTM and HaCaTM PAF-AHII cells
were irradiated with 400 J per m2 and incubated at 37°C. The cells were
harvested at time points as indicated. Caspase 3 speci®c enzymatic
activity was then assessed. Each point represents the mean 6 SD
percentage of the peak of caspase 3 speci®c activity from a typical
experiment from three separate experiments with similar results.
Figure 7. C2-ceramide-induced apoptosis in HaCaTM and
HaCaTM PAF-AHII cells. HaCaTM and HaCaTM PAF-AHII cells
were treated with 100 mM of C2 ceramide and incubated at 37°C. The
cells were harvested at time points as indicated. Caspase 3 speci®c
enzymatic activity was then assessed. Each point represents the mean 6
SD percentage of the peak of caspase 3 speci®c activity from a typical
experiment from three separate experiments with similar results.
Figure 5. t-BuOOH-induced apoptosis in HaCaTM and
HaCaTM PAF-AHII cells. HaCaTM and HaCaTM PAF-AHII cells
were treated with 100 mM t-BuOOH and incubated at 37°C. The cells
were harvested at time points as indicated. Caspase 3 speci®c enzymatic
activity was then assessed. Each point represents the mean 6 SD of
caspase 3 speci®c activity from a typical experiment from three separate
experiments with similar results.
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In this paper we present evidence that PAF-AHII is expressed in
a restricted pattern in human skin. Immuno¯uorescence, northern
blotting, and enzymatic assays demonstrate that PAF-AHII is
expressed in keratinocytes. The highest levels of PAF-AHII
expression are found in sebaceous glands, however, including the
sebaceous gland cell line SZ95, shown to exhibit major character-
istics of human sebocytes in vitro (Zouboulis et al, 1999). This
higher level of PAF-AHII expression in sebaceous glands, which
have a high lipid content, ®ts with an increased need of this tissue
to protect itself against oxidatively modi®ed phospholipids. It may
also indicate a protective action of the sebaceous glands on other
neighboring skin structures against oxidative stress via a paracrine
pathway.
To evaluate potential protective effects of PAF-AHII on
pro-oxidative stressors in keratinocytes, a replication-de®cient
retrovirus was used to stably overexpress this enzyme in HaCaT
cells. As shown in Fig 4, HaCaTM PAF-AHII cells had an
approximately 300% increase in baseline PAF-AH enzymatic
activity over baseline HaCaTM cells. This moderate overexpression
of PAF-AHII resulted in protection against the cytotoxic effects of
t-BuOOH and UVB irradiation. The protection was manifested as
a delay in the onset of apoptosis induced by these oxidative
stressors. That PAF-AHII did not fully protect against the cytotoxic
effects of these agents is compatible with the notion that other
targets for UVB and t-BuOOH that are independent of oxidized
phospholipids also play an important role. Increased levels of PAF-
AHII, however, did not affect apoptosis induced by C2 ceramide, a
nonoxidative stressor. These ®ndings ®t with previous studies
where overexpression of PAF-AHII was found to be protective
against t-BuOOH-induced apoptosis (Matsuzawa et al, 1997).
Although all these studies point to a protective effect of
overexpression of this enzyme on oxidative stress, we have found
that high levels of overexpression (4000%±8000%) in HaCaT or
KB cells using a mammalian expression vector result in increased
levels of both spontaneous and t-BuOOH-induced apoptosis (data
not shown). These ®ndings might be explained by recent studies
demonstrating that PAF-AHII has the ability to transfer the short
chain sn-2 group to sphingosine, producing short-chained
ceramides including C2 ceramide, which has known cytotoxic
effects (Karasawa et al, 1999). Thus, this enzyme not only can
inactivate PAF and related short-chained sn-2 phopsholipids, but
can generate other diverse lipid mediators.
Both oxidized lipids and the PAF system appear to have the
potential to modulate cutaneous in¯ammation as well as to have
cytotoxic effects. Our studies demonstrate that PAF-AHII, a novel
phospholipase that serves to regulate levels of both, is found in
human skin. Moderate overexpression of PAF-AHII in the human
keratinocyte cell line HaCaT protects against oxidative stressors
in vitro, suggesting that this enzyme could be involved in protecting
skin from oxidative damage in vivo. In addition, this enzyme has
anti-in¯ammatory effects through its ability to degrade PAF.
Though genetic mutations with resultant clinical effects have been
described for other forms of PAF-AHs in humans, it is not known
whether PAF-AHII mutations are associated with disease. Future
studies are planned to examine PAF-AHII levels in human skin
diseases that are associated with exaggerated responsiveness to
oxidative stress, including photosensitivity disorders.
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